

1 **Inferring MHC interacting SARS-CoV-2 epitopes recognized by TCRs towards designing T cell-**  
2 **based vaccines**

3 Amir Hossein Mohseni<sup>1,#</sup>, Sedigheh Taghinezhad-S<sup>1,#</sup>, Bing Su<sup>1</sup>, Feng Wang<sup>1\*</sup>

4 1. Shanghai Institute of Immunology, Translational Medicine Center, Shanghai General Hospital, State Key  
5 Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine,  
6 Shanghai, China

7 # Equal contribution

8

9 **Running Title:** T cell vaccine based on SARS-CoV-2 epitopes and TCR-MHC complex

10

11 **\*Corresponding author:**

12 Dr. Feng Wang

13 Shanghai Institute of Immunology, Translational Medicine Center, Shanghai General Hospital, State Key  
14 Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine,  
15 Shanghai, China

16 E-mail address: wangfeng16@sjtu.edu.cn

17

18 **Abstract**

19 The coronavirus disease 2019 (COVID-19) is triggered by severe acute respiratory syndrome mediated by  
20 coronavirus 2 (SARS-CoV-2) infection and was declared by WHO as a major international public health  
21 concern. While worldwide efforts are being advanced towards vaccine development, the structural  
22 modeling of TCR-pMHC (T Cell Receptor-peptide-bound Major Histocompatibility Complex) regarding  
23 SARS-CoV-2 epitopes and the design of effective T cell vaccine based on these antigens are still  
24 unresolved. Here, we present both pMHC and TCR-pMHC interfaces to infer peptide epitopes of the  
25 SARS-CoV-2 proteins. Accordingly, significant TCR-pMHC templates (Z-value cutoff > 4) along with  
26 interatomic interactions within the SARS-CoV-2-derived hit peptides were clarified. Also, we applied the  
27 structural analysis of the hit peptides from different coronaviruses to highlight a feature of evolution in  
28 SARS-CoV-2, SARS-CoV, bat-CoV, and MERS-CoV. Peptide-protein flexible docking between each of  
29 the hit peptides and their corresponding MHC molecules were performed, and a multi-hit peptides vaccine  
30 against the S and N glycoprotein of SARS-CoV-2 was designed. Filtering pipelines including antigenicity,  
31 and also physiochemical properties of designed vaccine were then evaluated by different  
32 immunoinformatics tools. Finally, vaccine-structure modeling and immune simulation of the desired  
33 vaccine were performed aiming to create robust T cell immune responses. We anticipate that our design  
34 based on the T cell antigen epitopes and the frame of the immunoinformatics analysis could serve as  
35 valuable supports for the development of COVID-19 vaccine.

36

37 **Keywords:** COVID-19, SARS-CoV-2, Immunoinformatics, MHC, TCR, vaccine.

38

39

40

41 **Declarations**

42 **Funding**

43 This study was supported by grants from the National Key Research and Development Program of China  
44 (SQ2018YFA090045-01), the National Natural Science Foundation of China (81771739), the Program for  
45 Professor of Special Appointments (Eastern Scholar) at Shanghai Institutions of Higher Learning, the  
46 Technology Committee of Shanghai Municipality (18JC1414100, 20410713800), the Innovative Research  
47 Team of High-level Local Universities in Shanghai, the SJTU Global Strategic Partnership Fund (2020  
48 SJTU-HUJI) and the SII Challenge Fund for COVID-19 Research.

49 **Conflicts of interest/Competing interests**

50 The authors declare that they have no conflicts of interest.

51 **Availability of data and material (data transparency)**

52 Not applicable

53 **Code availability (software application or custom code)**

54 Not applicable

55 **Authors' contributions**

56 Amir Hossein Mohseni and Sedigheh Taghinezhad-S contributed equally to this work. Also, all authors  
57 discussed the results, commented on the manuscript, and approved the final manuscript.

58

59 **Introduction**

60 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is determined as the causative agent  
61 of coronavirus disease 2019 (COVID-19) by public health professionals [1]. At the time of writing this  
62 manuscript, researchers tend to focus their attention on describing the immune response against SARS-  
63 CoV-2-derived B and T cell epitopes [2-4]. Although considerable efforts have been spent on clarifying the  
64 SARS-CoV-2 epitopes, the used approaches often lack accurate T cell receptor (TCR) and peptide-bound  
65 major histocompatibility complex (pMHC) binding models, which are crucial to initiate adaptive immunity  
66 [5-10]. Thus, little is known about the relationship between an effective adaptive immune response and the  
67 SARS-CoV-2 epitopes.

68 The recognition of antigen is a critical factor in T cell activation [11]. It has been well documented that the  
69 TCR plays a key role in activating cell-mediated adaptive immune responses. In this process, the TCR  
70 recognizes a peptide, obtained from a protein antigen, presented by MHC molecules, resulting in the  
71 initiation of downstream signaling pathways within the T cell. Moreover, immunological studies have  
72 found that MHC molecules will present selective peptides derived from a protein, indicating the significant  
73 impact of predicting peptide-MHC binding towards identification of potential T cell epitopes [12]. These  
74 findings acknowledge the necessity of further studies to provide insights into TCR-pMHC interactions and  
75 binding mechanisms in order to select optimal peptide antigen (Hit peptide) for eliciting potent immune  
76 responses against infectious diseases [13, 14]. In keeping with these observations, deep understanding of  
77 the peptides originating from the SARS-CoV-2 proteins that could elicit T cell mediated immune response  
78 may help in quest for the better development of a rational design of COVID-19 vaccine. To address these  
79 issues, we applied a novel computational framework to calculate the interaction between TCRs and SARS-  
80 CoV-2 antigen peptides whose recognition is restricted by human leukocyte antigen (HLA). Efficient  
81 structural modeling of TCR-pMHC interaction from SARS-CoV-2 proteins could identify the appropriate  
82 hit peptide(s), that with the following immunoinformatics analysis relating to the potential epitopes, is  
83 expected to provide a beneficial data source for the development of COVID-19 vaccine.

84

## 85 **Materials and Methods**

### 86 **Retrieving protein sequences**

87 All full-length protein sequences of envelope protein (E), membrane glycoprotein (M), nucleocapsid  
88 phosphoprotein (N), open reading frame 1ab polyprotein (ORF1ab), ORF3a protein (ORF3a), ORF6  
89 protein (ORF6), ORF7a protein (ORF7a), ORF8 protein (ORF8), ORF10 protein (ORF10), and surface  
90 glycoprotein (S) of SARS-CoV-2 in FASTA format from different geographic regions including: China,  
91 Wuhan (GenBank: MN90894) (as a reference SARS-CoV-2 isolate), India (Genbank: MT050493), Italy  
92 (Genbank: MT066156), Nepal (Genbank: MT072688), Sweden (Genbank: MT093571), Brazil (Genbank:  
93 MT126808), China (Genbank: MT135041), Taiwan (Genbank: MT192759), Viet Nam (Genbank:  
94 MT192773), Spain (Genbank: MT198652), Pakistan (Genbank: MT240479), Colombia (Genbank:  
95 MT256924), Peru (Genbank: MT263074), USA (Genbank: MT276329), and South Korea (Genbank:  
96 MT304474) were retrieved from the GenBank (<https://www.ncbi.nlm.nih.gov/genbank/>) at the first of April  
97 2020. Also, the entire viral proteome sequences from bat-CoV (Genbank: MG772921), MERS-CoV  
98 (Genbank: KF958702), and SARS-CoV (Genbank: AY390556) were retrieved for further comparison  
99 between the SARS-CoV-2 derived hit peptides and other coronaviruses.

100

### 101 **Modeling of TCR–pMHC complex**

102 The sequences of each protein were aligned using the CLC sequence viewer (Version 6.7.1). For  
103 computing the final alignment, the sequences showing poor alignments were deleted and finally the  
104 consensus sequences of each protein were extracted for using as an input for modeling of TCR–pMHC.  
105 Then, each protein sequence in FASTA format was allocated by PAComplex server to forecast a model of  
106 9- to 11-mer peptides bound to HLA-A0201, HLA-B0801, HLA-B3501, HLA-B3508, HLA-B4405, and  
107 HLA-E-peptide-TCR template with Z values > 4.0 [15]. Moreover, an in-depth interaction among atoms,  
108 model of binding, and amino acid sequences related to homologous peptide antigens were evaluated for  
109 each query. Then, in order to evaluate the conserved regions and pairwise identity among SARS-CoV-2-  
110 derived hit peptide and other coronaviruses including SARS-CoV, MERS-CoV, and bat-CoV multiple  
111 sequence alignment (MSA) was performed.

## 112 **Prediction of immunogenicity of the SARS-CoV-2-derived hit peptide**

113 Each SARS-CoV-2-derived hit peptide by same length that presented on the same HLA class I molecule  
114 were analyzed through evaluation of the amino acid characteristics by T cell class I pMHC immunogenicity  
115 tool [16]. Prediction results were sorted by descending score values. The higher score was indicated as a  
116 greater probability of eliciting an immune response.

117

## 118 **Study the binding mechanisms and interatomic interactions**

119 For each hit peptides, hydrogen bonds (H-bond) and van der Waals (VDW) forces of pMHC and peptide-  
120 TCR interfaces were calculated. Also, in order to study the atom–atom contacts, Arpeggio server was used  
121 for detailed evaluation of TCR-pMHC complex derived from SARS-CoV-2 proteins. Accordingly, protein  
122 structure and visualization of the measured interactions between atoms including the strongest mutually  
123 exclusive interactions, polar contacts, H-bonds, ionic interactions, aromatic contacts, hydrophobic contacts,  
124 and carbonyl interactions were showed by WebGL-based protein structure viewer and PyMOL session  
125 based-visualization.

126

## 127 **Peptide-protein flexible docking**

128 One of the significant tools for designing of drug is computational docking methods. So, the usage of  
129 innovative methods including protein-peptide docking for quick development of peptide therapeutics in  
130 rational drug design is unavoidable. In this study, template-based docking and 3D protein-peptide complex  
131 structures from input protein structure and peptide sequence were predicted by GalaxyPepDock server  
132 (<http://galaxy.seoklab.org/cgi-bin/submit.cgi?type=PEPDOCK>) through merging information on analogous  
133 interactions in the structure database and energy-based optimization in order to expect the formation of  
134 MHC-peptide complex. Then, the contacting residues in the template structure to the template amino acids  
135 was aligned by similarity of the amino acids of the target complex and an interaction similarity score was  
136 defined for it by server. This analysis presented an example of MHC-peptide docking performed by each  
137 individual hit peptides derived from N and S proteins and available PDB file of HLA alleles including  
138 HLA-A0201 (PDB: 5yxn), HLA-B3501 (PDB: 1a9e), HLA-B0801 (3spv), HLA-B3508 (3bw9), HLA-  
139 B4405 (3dx8), and HLA-E (2esv), separately.

#### 140 **Designing of multi-hit peptides vaccine sequence**

141 A set of high immunogenic hit peptides derived from N and S proteins of SARS-CoV-2 with high binding  
142 events to HLA-A0201, HLA-B0801, HLA-B3501, HLA-B3508, HLA-B4405, and HLA-E were selected  
143 on the basis of their solvent exposed residues and hydrophobicity scales. The AAY and GPGPG linkers  
144 were applied for linking the candidate N and S hit peptides together, respectively. Additionally, the human  
145 beta defensin 3 was also joined at N-terminus of the vaccine construct using EAAAK linker which acts as  
146 adjuvant to improve the immunogenicity of the multi-hit peptides vaccine.

147

#### 148 **Prediction of allergenicity, antigenicity, and physicochemical properties of designed vaccine**

149 The allergenicity of query sequence was evaluated using AllergenFP v.1.0 server ([http://ddg-](http://ddg-pharmfac.net/AllergenFP/)  
150 [pharmfac.net/AllergenFP/](http://ddg-pharmfac.net/AllergenFP/)). Vaccine construct was analyzed by VaxiJen v2.0 ([http://www.ddg-](http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html)  
151 [pharmfac.net/vaxijen/VaxiJen/VaxiJen.html](http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html)) with high accuracy at 0.4 thresholds for virus. Also,  
152 ProtParam web server (<https://web.expasy.org/protparam/>) was used to predict various physicochemical  
153 properties of vaccine construct including like theoretical isoelectric point (pI), in vitro and in vivo half-life,  
154 amino acid composition, molecular weight, instability and aliphatic index, and grand average of  
155 hydropathicity (GRAVY).

156

#### 157 **Vaccine-structure modeling**

158 The SOPMA web server ([https://npsa-prabi.ibcp.fr/cgi-bin/npsa\\_automat.pl?page=npsa\\_sopma.html](https://npsa-prabi.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_sopma.html)) was  
159 utilized for the computation the secondary structure of multi-hit peptides vaccine. Indeed, I-TASSER server  
160 (<https://zhanglab.ccmb.med.umich.edu/I-TASSER/>), as an algorithm for fast and accurate de novo protein  
161 structure prediction, was further employed to predict the solvent accessibility, 3-dimensional structure (3D),  
162 and function of the vaccine sequence. In detail, I-TASSER by recruiting SPICKER program groups all the  
163 decoys according to the pair-wise structure similarity and provides five models that are linked to the five  
164 largest structure clusters. This server determines the confidence of each model by C-score which typically  
165 is in the range of (-5, 2). A model with a higher confidence has higher C-score than a model with a lower  
166 confidence. Also, prediction of TM-score and RMSD was done by I-TASSER server according to the C-  
167 score and protein length after obvious connection between these qualities.

168 **Refinement of tertiary structure and validation**

169 The refinement of the tertiary structure of vaccine was carried out using 3D<sup>refine</sup> server  
170 (<http://sysbio.rnet.missouri.edu/3Drefine/index.html>) which is based on the CASP10 tested refinement  
171 method for protein's side chain reconstruction, molecular dynamics simulation, and repacking to relax the  
172 3D structure. Then, to fulfill the validation of 3D structure, output model of 3D<sup>refine</sup> server was subjected to  
173 the ProSA-web server (<https://prosa.services.came.sbg.ac.at/prosa.php>). Overall quality of the model with  
174 Z-score index was anticipated for model by the server. The outside range of Z-score value for the predicted  
175 model will point to the invalid structure of the model. Indeed, RAMPAGE server  
176 (<http://molprobioty.biochem.duke.edu/>) also was used to determine the overall quality of the predicted model  
177 of the multi-hit peptides vaccine following Ramachandran plot analysis.

178

179 **Immune simulation**

180 To further characterize immune response profile of multiple hit-peptide protein, FASTA format of our  
181 multi-hit peptides vaccine was subjected to C-ImmSim server (<http://150.146.2.1/C-IMMSIM/index.php>)  
182 for computing T cell immune response. C-ImmSim is an agent-based model that can predict immune  
183 epitope and immune interactions by using PSSM (a position-specific scoring matrix) and machine learning  
184 techniques, respectively. It instantaneously induces three compartments in three distinct anatomical regions  
185 (bone marrow thymus, a tertiary lymphatic organ). As such, three injections with time steps set at 1, 84, and  
186 168 were given four weeks apart along an injection without LPS. Also, host HLA were selected for HLA-  
187 A0201, HLA-A0101, HLA-B0801, HLA-B3508, and HLA-DRB1\_0101. Nevertheless, the simulation  
188 volume and simulation steps were set based on the default parameters.

189

190 **Statistical analysis and data availability**

191 In our theoretical study, no statistical analyses were performed according to the literature data and web-  
192 accessible databases. All data presented in the present study are summarized in the complementary figures,  
193 tables, and supplemental materials.



194

## 195 **Results and Discussion**

### 196 **Overview of the potential TCR–pMHC binding models for SARS-CoV-2 proteins:**

197 According to TCR–pMHC binding models, for N query, one hit peptide antigen candidate  
198 (105SPRWYFYYL113) with Z-value cutoff > 4 and 61 homologous peptide antigens in 34 organisms was  
199 found by using HLA-A0201-peptide-TCR template [PDB entry 2vlr] and the experimental peptide database.  
200 It was documented that E, M, and ORF10 protein queries have two hit peptide antigen candidates (Z-value  
201 cutoff > 4). Also, 108, 80, and 40 homologous peptide antigens in 56, 40, and 25 organisms by using HLA-  
202 A0201-peptide-TCR template [PDB entry 1qrn, 2jcc, and 1oga] and the experimental peptide database was  
203 identified for them, respectively. Giving our data, five and ten hit peptide antigen candidates (Z-value  
204 cutoff > 4), and 23 and 40 homologous peptide antigens in 16 and 25 organisms by using HLA-A0201-  
205 peptide-TCR template [PDB entry 2p5e and 1oga] and the experimental peptide database were inferred in  
206 ORF3a and S proteins, respectively. No hit peptide antigen candidates with Z-value cutoff > 4 were  
207 detected for ORF6, ORF7a, and ORF8 queries by using HLA-A0201-peptide-TCR template (Figure S1A).  
208 Our results showed that by using HLA-B0801 (Figure S1D), HLA-B3501 (Figure S1B), and HLA-B3508  
209 (Figure S1E) template, TCR-pMHC models with Z-value cutoff > 4 were only predicted for S (5 hit peptide  
210 antigen candidate and 91 homologous peptide antigens in 57 organisms with PDB entry 1mi5), N (3 hit  
211 peptide antigen candidate and 3 homologous peptide antigens in 2 organisms with PDB entry 2nx5), and S  
212 (1 hit peptide antigen candidate and 1 homologous peptide antigens in 1 organisms with PDB entry 2ak4)  
213 proteins, respectively. While, only M and S proteins were used to predict TCR-pMHC complex by using  
214 HLA-B4405 (Figure S1C) with PDB entry 3dxa (15 homologous peptide antigens in 12 organisms). Also  
215 only N, ORF10, and S proteins were used for prediction of TCR-pMHC complex by HLA-E (Figure S1F)  
216 with PDB entry 2esv (84 homologous peptide antigens in 41 organisms) with Z-value cutoff > 4. No hit  
217 peptide antigen candidates with Z-value cutoff > 4 were detected for M, E, and ORF3a queries by using  
218 HLA-E-peptide-TCR template (Figure S1F). Moreover, model for ORF1ab query did not predict due to its  
219 sequence length was  $\geq 300$ . The 3D structure of the TCR–pMHC complex for each hit peptide derived  
220 from each protein was illustrated by SWISS-MODEL. Detailed information about derived hit peptides for  
221 SARS-CoV-2 along with bat-CoV, MERS-CoV, and SARS-CoV were tabulated in Table 1.

222

223 **The binding events among hit peptides derived from N proteins related to HLA-A0201**

224 Our TCR-pMHC models predicted that position 2 of the homologous peptide antigens (Figure 1A) related  
225 to TCR-pMHC complex of SARS-CoV-2 as well as SARS-CoV and bat-CoV N proteins prefers the  
226 hydrophobic amino acid residues (e.g. Ile, Leu, Met, and Phe), and the second position of these hit peptides  
227 is an hydrophobic amino acid residue Pro forming five strong VDW forces with residues Y99, V67, M45,  
228 Y7, and F9 and two H-bonds with residues K66 and E63 on MHC molecule (Figure S2A, left). By contrast,  
229 the second position of MERS-CoV N protein-derived hit peptide is charged residue Arg forming three  
230 strong VDW forces with residues M45, F9, and V67 and two H-bonds with residues K66 and E63 (As  
231 same as SARS-CoV-2) on MHC molecule. Surprisingly, position 9 of all homologous peptides antigens  
232 (Figure 1A) prefers the hydrophobic amino acid residues (e.g. Leu, Ile, Val, and Met), and the position 9 of  
233 these hit peptides is hydrophobic amino acid residue Leu (in the SARS-CoV-2, SARS-CoV, and bat-CoV)  
234 and Gly (in the MERS-CoV). Our results showed that Leu attaches to the MHC with three strong VDW  
235 forces with residues L81, I124, and W147 and three H-bonds with residues D77, Y84, and T143, while Gly  
236 forms three strong VDW forces with residues L81, V95, and W147 and two H-bonds with residues D77  
237 and V95 on MHC molecule (Figure S2A, left). Moreover, positions 4, 6, and 8 of hit peptides in SARS-  
238 CoV-2, SARS-CoV, and bat-CoV form one H-bond with residues Q52, Q52 and D32 in chain E of TCR,  
239 respectively (Figure S2C, left). While, only position 4 of hit peptides in MERS-CoV forms one H-bond  
240 with residue S100 in chain D of TCR (Table S1). Visualization of interactions in the atomic level structure  
241 of a TCR-pMHC complex in the hit peptide of SARS-CoV-2 N protein for HLA-A0201 (Figure S3A)  
242 within 20 and 8 Å generated on-the-fly using PyMOL.

243

244 **The binding events among hit peptides derived from N proteins related to HLA-E**

245 Our models proposed that positions 1, 2, 7, 8, and 9 of the homologous peptide antigens (Figure 1B) of  
246 SARS-CoV-2, bat-CoV, MERS-CoV, and SARS-CoV prefer the hydrophobic amino acid residues.  
247 Accordingly, position 1 of these hit peptides forms two H-bonds with residues Y170 and Y158 and position  
248 2 of these hit peptides forms a H-bonds with residue E62 and four strong VDW forces with residues A66,  
249 Y6, W96, and M44. Moreover, position 7 of these hit peptides forms a H-bond with residue N76 and three

250 strong VDW forces with residues L123, F115, and W132. (Figure S2A, center). We identified position 4 of  
251 hit peptides lacks any contacts, although the position 5 and 6 of hit peptides form both H-bonds and/or  
252 strong VDW forces on both MHC molecule and TCR (Figure S2A and S2C, center) (Table S2).  
253 Visualization of interactions in the atomic level structure of a TCR-pMHC complex in the hit peptide of  
254 SARS-CoV-2 N protein for HLA-E (Figure S3C) within 20 and 8 Å was generated on-the-fly using  
255 PyMOL.

256

### 257 **The binding events among hit peptides derived from N proteins related to HLA-B3501**

258 Position 1 of the homologous peptide antigens (Figure 1C) of TCR-pMHC complex of N protein in the  
259 SARS-CoV-2, bat-CoV, and SARS-CoV prefers the charged amino acid residues (e.g. Glu and Asp), and  
260 the first position of all hit peptides is polar amino acid forming four H-bonds with residues R62, Y171, Y7,  
261 and Y159 on MHC molecule (Figure S2A, right) and one H-bond with residue Y96 on TCR (Figure S2C,  
262 right). Also, position 2 of the homologous peptide antigens in SARS-CoV-2, SARS-CoV, and bat-CoV  
263 prefers the hydrophobic amino acid residues (e.g. Pro, Ala, and Ile) and the position 2 of these hit peptides  
264 forms three strong VDW contacts with residues Y159, Y7, and Y99 on MHC molecule (Figure S2A, right).  
265 Interestingly, based on the binding models and interactions, positions 6, 8, and 9 of all hit peptides  
266 correlated with the SARS-CoV-2, bat-CoV, and SARS-CoV lack any H-bonds and strong VDW contact,  
267 while the hit peptides of all comparison targets correlate well with the amino acid profile on the conserved  
268 positions (i.e. 4 and 7) forming one strong VDW forces and two H-bonds based on the interactions on TCR  
269 (Figure S2C, right) (Table S3). Visualization of interactions in the atomic level structure of a TCR-pMHC  
270 complex in the hit peptide of SARS-CoV-2 N protein for HLA-B3501 (Figure S3B) within 20 and 8 Å was  
271 generated on-the-fly using PyMOL.

272

### 273 **The binding events among hit peptides derived from S proteins related to HLA-B3508**

274 Position 1 and 11 of the homologous peptide antigens (Figure 1D) in TCR-pMHC complex in all  
275 comparison targets, excluding MERS-CoV, prefer the hydrophobic amino acid residues (e.g. Leu, Phe, Ile,  
276 Ala, and Pro), and the first position of the hit peptides is residue Leu forming three H-bonds with residues  
277 Y159, Y7, and Y171 and two strong VDW contacts with residues W167 and L163 on MHC molecule

278 (Figure S2B, left). Also, position 11 is residue Ala forming one strong VDW contacts with residue W147  
279 on MHC molecule (Figure S2B, left). We found that the position 10 of hit peptides lacks any H-bond and  
280 strong VDW forces, while the positions 5 and 6 of hit peptides in the SARS-CoV-2, bat-CoV, and SARS-  
281 CoV form one strong VDW forces on MHC molecule (Figure S2B, left) and two strong VDW forces on  
282 TCR (Figure S2D, left). Additionally, position 6 forms one H-bond on TCR (Figure S2D, left) (Table S4).  
283 Visualization of interactions in the atomic level structure of a TCR-pMHC complex in the hit peptide of  
284 SARS-CoV-2 S protein for HLA-B3508 (Figure S3E) within 20 and 8 Å was generated on-the-fly using  
285 PyMOL.

286

### 287 **The binding events among hit peptides derived from S proteins related to HLA-B4405**

288 Hit peptide derived from SARS-CoV-2 as same as bat-CoV, MERS-CoV, and SARS-CoV correlates well  
289 with the amino acid profile on the conserved positions (i.e. 4, 5, 7, and 8) and all of them form one strong  
290 VDW forces with residue I66, V152, and A150 based on the interactions of pMHC interfaces in HLA-  
291 B4405-peptide-TCR template (3dxa), respectively. In spite of that, position 9 of all queries forms two H-  
292 bonds with residue E76 and W147 on MHC (Figure S2B, center) and one strong VDW forces and two H-  
293 bonds on TCR (Figure S2D, center). Based on the interactions of hit peptides with TCR, position 4, 5, and  
294 7 form one, three, and two strong VDW forces, respectively. Also, position 8 of the homologous peptide  
295 antigens (Figure 1E) in all queries prefers the hydrophobic amino acid residues (e.g. Val, Ala, and Leu) and  
296 the position 8 of these hit peptides (excluding MERS-CoV) is polar amino acid residue Gln forming one  
297 strong VDW contacts with residue V152 on MHC molecule (Figure S2B, center). Whereas position 6 of hit  
298 peptides attaches to the TCR molecule with two H-bonds (Figure S2D, center) (Table S5). Visualization of  
299 interactions in the atomic level structure of a TCR-pMHC complex in the hit peptide of SARS-CoV-2 S  
300 protein for HLA-B4405 (Figure S3F) within 20 and 8 Å was generated on-the-fly using PyMOL.

301

### 302 **The binding events among hit peptides derived from S proteins related to HLA-B0801**

303 As pointed out, positions 2 and 9 of the homologous peptide antigens (Figure 1F) of TCR-pMHC complex  
304 related to all queries prefer the hydrophobic amino acid residues (e.g. Leu, Ile, Met) and the second  
305 position of these hit peptide in SARS-CoV-2, bat-CoV, and SARS-CoV is polar amino acid residue Ser and

306 in MERS-CoV is hydrophobic amino acid residue Pro forming two strong VDW forces with residues I66  
307 and F36, and one H-bond with residue N63 on MHC molecule (Figure S2B, right). Conversely, position 4  
308 of the homologous peptide antigens of all queries has no detectable binding to both MHC and TCR.  
309 Additionally, position 6 of these hit peptides with a H-bond and strong VDW forces connects to the  
310 residues Q96 and Y96 on TCR, respectively (Figure S2D, right). The hit peptide correlates well with the  
311 amino acid profile on the conserved positions 7 (Tyr) that forms one strong VDW forces with residue  
312 W147 on MHC (Figure S2B, right) and four strong VDW forces with residue A97, H47, H32, and L90 on  
313 TCR (Figure S2D, right and Table S6). Visualization of interactions in the atomic level structure of a TCR-  
314 pMHC complex in the hit peptide of SARS-CoV-2 S protein for HLA-B0801 (Figure S3D) within 20 and 8  
315 Å was generated on-the-fly using PyMOL.

316

### 317 **Immunogenicity study for SARS-CoV-2 protein derived peptide antigens**

318 Prediction the immunogenicity of a class I peptide MHC complex showed that the top putative  
319 immunogenic SARS-CoV-2-derived hit peptide candidates related to HLA-A0201 based on their score  
320 were 105SPRWYFYLYL113 (derived from N protein), 5NVFAPPFTI13 (derived from ORF10 protein),  
321 19LFLAFVVFL27 (derived from E protein), and 145YFLCWHTNC153 (derived from ORF3a protein),  
322 respectively. Interestingly, the hit peptides derived from N and E proteins of SARS-CoV-2 by using HLA-  
323 A0201 were similar to the peptides derived from N and E proteins of bat-CoV and SARS-CoV, and all of  
324 them had higher immunogenicity in comparison to hit peptides derived from MERS-CoV N and E proteins.  
325 This result generally was consistent with the result of Grifoni et al., who showed that the sequence of  
326 protein consensus of SARS-CoV-2 was similar to the protein sequence of SARS-CoV and bat-CoV, but  
327 was more different from protein consensus of MERS-CoV [17]. More specifically, our results showed that  
328 the hit peptide derived from ORF3a of SARS-CoV-2 was similar to the hit peptide derived from bat-CoV  
329 protein 3, and both of them had higher immunogenicity in comparison to hit peptide derived from MERS-  
330 CoV and SARS-CoV ORF3 proteins. Our data emphasized the hit peptide derived from SAR-CoV-2 S  
331 protein by using HLA-A0201 had lower immunogenicity than bat-CoV, MERS-CoV, and SARS-CoV.  
332 Additionally, regarding HLA-E, comparison of SARS-CoV-2 N-derived hit peptide (DLSPRWYFY) to  
333 sequences for bat-CoV (ELSPRWYFY), MERS-CoV (QLAPRWYFY), and SARS-CoV (ELSPRWYFY)

334 revealed a high degree of immunogenicity between SARS-CoV-2, SARS-CoV, and bat-CoV but a more  
335 limited immunogenicity with MERS-CoV.

336 Based on the hypothesis that solvent exposed residues via increasing TCR binding can provide appropriate  
337 evidence about peptide immunogenicity, we measured solvent exposed area (SEA) for each hit peptide.  
338 Our results displayed that the SEA > 30 Å<sup>2</sup> for hit peptide related to HLA-B0801, HLA-B3501, and HLA-  
339 B3508 were 5.08, 7.76, and 8.28, respectively. Indeed, we found the most solvent accessibility of amino  
340 acids were in the hit peptide M (SEA > 30 Å<sup>2</sup>: 5.99), S (SEA > 30 Å<sup>2</sup>: 6.75), and ORF10 (SEA > 30 Å<sup>2</sup>: 6)  
341 for HLA-A0201, HLA-B4405, and HLA-E, respectively.

342 Over the past few months, studies in humans are beginning to unravel the underpinnings relationship  
343 between hydrophobicity scales and eradication of immune responses. Currently, identification of peptide  
344 regions exposed at the surface has gained much attention in the field of immunogenicity of peptides  
345 presented by MHC. This concept is reinforced when we investigate the hydrophobic solvent accessible  
346 surface area (hSASA) for each peptide. As such, to account for immunogenicity of MHC-presented  
347 peptides, we relied on the hydrophobicity of each peptide position. Further, we evaluated whole-residue  
348 hydrophobicity scales among all hit peptides by using the Wimley-White whole-residue hydrophobicity  
349 scales to examine how structural characteristics could result in enhanced immunogenicity predictions. Our  
350 results are supported by those obtained from IEBD, related to HLA-A0201-peptide-TCR templates showed  
351 that specific locations with the most pronounced variations at positions 4, 6, 7, 8, and 9 across the peptides  
352 derived from N protein were more hydrophobic in the immunogenic dataset than the peptide derived from  
353 M protein (Figure 2A). Our result also showed that the hit peptide antigens derived from N protein related  
354 to HLA-E-peptide-TCR (Figure 2E) and S protein related to HLA-B4405 peptide-TCR (Figure 2D) had  
355 grater hydrophobicity than ORF10 and M proteins due to differences at positions 6 and 9, and 5,  
356 respectively. These observations indicate that hit peptide antigens derived from N and S proteins properly  
357 contain immunogenic amino acids. Similarly, positions 8, 10, and 11 across the peptides derived from N,  
358 positions 1, 4, 6, 7, and 9 across the peptides derived from S, and positions 1, 4, 5, and 12 across the  
359 peptides derived from S proteins (by HLA-B3501 (Figure 2B), HLA-B0801 (Figure 2C), and HLA-B3508  
360 (Figure 2F) had high score of hydrophobicity based on their amino acid sequence, respectively.

361 In line with our findings, a landmark study by Grifoni et al. has supporting evidence for the detrimental  
362 association between the incidence of CD4<sup>+</sup> and CD8<sup>+</sup> response against the N and S proteins in humans with  
363 COVID-19 Disease [3]. Consistent with this, there are evidence suggesting that the S protein of SARS-  
364 CoV-2 is a promising option for induction of a protective immunity [18]. Sorting this relation out could  
365 enhance our understanding of the role of SARS-CoV-2 proteins in the context of T cell immunity. Of note,  
366 SARS-CoV-2-derived hit peptide from N and S proteins were selected for further analysis.

367

### 368 **Evaluation of SARS-CoV-2-derived hit peptides sequence conservation**

369 Next, we used CLUSTALW and CLC Sequence Viewer (Version 6.7.1) to calculate the percentage identity  
370 between SARS-CoV-2-derived hit peptide sequences and bat-CoV, MERS-CoV, and SARS-CoV. We  
371 found that HLA-A0201 binding hit peptide of SARS-CoV-2 N protein (Figure 3A) and the SARS-CoV-2 S  
372 proteins correlated with HLA-B3508 (Figure 3F) and HLA-B0801 (Figure 3B) were more strongly  
373 conserved between bat-CoV and SARS-CoV (100% identity) in comparison with MERS-CoV (77.78%,  
374 69.23%, and 22.22% identity, respectively). We also identified that the hit peptide of SARS-CoV-2 N  
375 protein correlated to HLA-B3501 (Figure 3E) and HLA-E (Figure 3C) had 45.45% and 77.78% identity  
376 with MERS-CoV, and 90.91% and 88.89% with bat-CoV and SARS-CoV, respectively. Correspondingly,  
377 HLA-B4405 binding hit peptide of SARS-CoV-2 S protein (Figure 3D) had 25% identity with MERS-CoV,  
378 60% identity with bat-CoV, and 70% identity with SARS-CoV, suggesting high sequences similarity  
379 between hit peptides derived from N and S proteins of SARS-CoV-2, SARS-CoV, and bat-CoV compared  
380 to MERS-CoV.

381

### 382 **Assessment of residues interactions**

383 It has long been known that a potent immune response to hit peptides is mediated by the higher affinity and  
384 binding of the hit peptides to immune cells under optimal conformation. Better understanding of specific  
385 macromolecular interactions within the binding sites could help identifying molecular recognitions such as  
386 those occurring among targets and ligands, which are important for drug development. This knowledge is  
387 expected to open new application avenues for the designing of effective vaccines based on high prioritized  
388 epitopes that have strong affinity and binding to TCR and MHC. Different SARS-CoV-2-derived hit

389 peptides with immunogenicity prediction displayed that the maximum binding rate of chain C (hit peptide)  
390 in TCR-pMHC complex was linked to the N and S proteins, respectively. Apart from MERS-CoV, when  
391 we compared the hydrophobic contacts, mutually exclusive interactions, and polar contacts among different  
392 hit peptides by using HLA-A0201- (Figure S4A), HLA-B0801- (Figure S4B), HLA-B3508- (Figure S4D),  
393 and HLA-E-peptide-TCR template (Figure S4F), it was proved that these interactions were equal in chain C  
394 of TCR-pMHC complex associated with N and S proteins of SARS-CoV-2, bat-CoV, and SARS-CoV  
395 proteins. The above-mentioned interactions were lower in SARS-CoV-2 than bat-CoV and SARS-CoV  
396 associated with HLA-B3501 (Figure S4C) similarly to the hydrophobic contacts by using HLA-E (Figure  
397 S4F). By contrast, the number of aforementioned contents (excluding mutually exclusive interactions in  
398 SARS-CoV by using HLA-B4405 (Figure S4E)) was higher in SARS-CoV-2 than bat-CoV and SARS-  
399 CoV associated with HLA-B3508 (Figure S4D) as well as the number of polar contacts by HLA-E (Figure  
400 S4F). Correspondingly, in HLA-E, SARS-CoV-2-derived hit peptide had the lower mutually exclusive  
401 interactions compared to the bat-CoV and SARS-CoV. On the opposite side, this type of interatomic forces  
402 was higher in the SARS-CoV-2-derived hit peptide than MERS-CoV associated with HLA-E (Figure S4F,  
403 Table 2, and Table S7-S9).

404

#### 405 **Peptide-protein flexible Docking**

406 For various kinds of biological applications such as vaccine design, peptides have been introduced as  
407 potential candidates. Recently, several methods have been introduced for protein-peptide docking, which  
408 can estimate the structure of the protein-peptide complex through peptide sequence and protein structure.  
409 Accordingly, for hit peptides derived from N protein, NSSPDDQIGYY had the highest interaction  
410 similarity score with HLA-B3501 than SPRWYFYLL and DLSPRWYFY with HLA-A0201 and HLA-E,  
411 respectively. Moreover, for hit peptides derived from S protein, FSTFKCYGV had the highest interaction  
412 similarity score with HLA-B0801 than LQDVVNQNAQALN and NKKFLPFQQF with HLA-B3508 and  
413 HLA-B4405, respectively. Figure 4 represents a sample of successful docking model between each hit  
414 peptide and its MHC protein.

415

#### 416 **Multi-hit peptides vaccine and its structural properties**



417 On the basis of immunogenicity and hydrophobicity scale, and residues interactions, six hit peptides  
418 derived from N and S proteins related to HLA-A0201, HLA-B0801, HLA-B3501, HLA-B3508, HLA-  
419 B4405, and HLA-E including SPRWYFYYL, FSTFKCYGV, NSSPDDQIGYY, LQDVVNQNAQALN,  
420 NKKFLPFQQF, and DLSPRWYFY were joined together by linking the N and S hit peptides via AAY and  
421 GPGPG linkers. Additionally, the human beta defensin 3 was also attached to the N-terminus of the  
422 finalized vaccine construct using EAAAK linker which acts as adjuvant to improve the immunogenicity of  
423 the vaccine. Evaluation of the final vaccine construct amino acid sequences (comprising a length of 122  
424 amino acids) by BLASTp showed only 36% similarity which is due to the human  $\beta$ -defensin 3 sequence,  
425 proving this vaccine did not have any overlap with human proteins and could not elicit autoimmunity.  
426 Assessment the secondary structural of the vaccine using SOPMA server uncovered that it was composed  
427 of 17.21 % Alpha helix (Hh), 24.59 % Extended strand (Ee), 3.28 % Beta turn (Tt), and 54.92 % Random  
428 coil (Cc). The allergenicity and antigenicity of the finalized vaccine construct showed that the vaccine is  
429 non-allergenic and it has the antigenicity likelihood of 0.4838 with threshold of 0.4, characterizing the  
430 antigenic nature of our final multi-hit peptides vaccine for an adequate inducing of immune response. The  
431 molecular weight of vaccine construct and Theoretical protrusion index (pI) score was found to be  
432 13498.44 Da and 9.51 while the total numbers of negative and positive charge residues were 7 and 18  
433 respectively, confirming vaccine tendency to be antigenicity and its slightly acidic nature. Indeed, the  
434 estimated half-life was 30 hours (mammalian reticulocytes, *in vitro*), > 20 hours (yeast, *in vivo*), and >10  
435 hours (*Escherichia coli*, *in vivo*). The extinction coefficient was estimated to be  $19285 \text{ M}^{-1} \text{ cm}^{-1}$ , at 280 nm  
436 measured in water, assuming all pairs of cysteine residues form cystines. The instability index (II) was  
437 computed to be 47.60, showing unstable nature of vaccine in the experimental setup. Aliphatic index was  
438 calculated as 56.8 while Grand average of hydropathicity (GRAVY) was calculated -0.593.

439

#### 440 **Tertiary structure, refinement, and epitope mapping**

441 The three-dimensional (3D) structures supply vital insights into the tertiary structure and position of the hit  
442 peptides [19]. In the first step, the 3D structure of the multi-hit peptides vaccine with total 122 amino acid  
443 residues were modeled by using the I-TASSER web tool (Figure 5A) Accordingly, 5 final models were

444 predicted as a single domain without disorder. Among them, the first model had a better quality in most  
445 cases with C-score = -3.25, Estimated TM-score =  $0.35 \pm 0.12$ , and Estimated RMSD =  $11.7 \pm 4.5 \text{ \AA}$ .  
446 However, because of the modelling errors and unavailability of an appropriate template such as angles and  
447 irregular bonds, generation of the 3D models cannot be sufficient to follow the necessary accuracy level for  
448 some biological purpose, especially where experimental data is rare. As such, for modification of local  
449 errors, helping to bring 3D model of vaccine closer to native structures, and growing the accuracy of  
450 primary 3D model, the refinement of 3D structure of the vaccine is vital, particularly for furthering in-silico  
451 studies [20]. Therefore, the refinement of the model was performed by using 3D<sup>refine</sup> tool. On the basis of  
452 the overall quality of the refined model, the model 5 exhibited the best results with RMSD  $0.549 \text{ \AA}$  (Figure  
453 5B). The quality of the best model of the multi-hit peptides vaccine construct was validated by ProSA-web.  
454 It is well-known that the Z score is in relation with the length of the protein, indicating that negative Z-  
455 scores are more appropriate for a trustworthy model. In fact, the Z score shows the overall quality and  
456 calculates the deviation of the total energy related to the protein structure [21]. The Z score of the protein  
457 under study was displayed in the plot with a dark black point. Accordingly, our results revealed the  
458 improvement of the refined model of vaccine (Z score: -3.81) (Figure 5D) in comparison with initial model  
459 (Z score: 3.45) (Figure 5C), which was lying inside the scores range of the native proteins of similar size  
460 (range -20 to 10) and also was located within the space of protein related to X-ray, suggesting that the  
461 obtained model is reliable and closes to experimentally determined structure. Evaluation the overall quality  
462 of the finalized model of vaccine construct by Ramachandran plot analysis emphasized that 77.5% (93/120)  
463 of all residues in finalized model (Figure 5F) compared to 54.2% (65/120) of all residues in initial model  
464 (Figure 5E) were in favored (98%) regions, also, 90.0% (108/120) of all residues in finalized model (Figure  
465 5F) compared to 78.3% (94/120) of all residues in initial model (Figure 5E) were in allowed (>99.8%)  
466 regions. After that, protein structure and visualization of the measured interactions between atoms  
467 including the strongest mutually exclusive interactions, polar contacts, H-bonds, ionic interactions,  
468 aromatic contacts, hydrophobic contacts, and carbonyl interactions were compared together and analyzed  
469 by Arpeggio server and finally the results were tabulated in Table 3.

470

471 **Immune simulation**

472 C-ImmSim Immune simulator web server was used for determining ability of vaccine to induce T cell  
473 immunity. This server yielded results consistent with actual immune responses as evidenced by a general  
474 marked increase in the generation of secondary responses. For better following the effects of the final  
475 vaccine construct for stimulation of T cell immunity, a construct with point mutations on key residues,  
476 replacing of the hydrophobic amino acids with charged amino acids was constructed (Figure 6A).  
477 According to data, after vaccination with native vaccine, there was a consistent rise in Th (helper) cell  
478 population with memory development compared to control (Figure 6B-E). Interestingly, immune  
479 simulation results demonstrated that while a notable activation of TC (cytotoxic) was observed after  
480 vaccination with native vaccine, an activation was not observed after vaccination with the mutant vaccine,  
481 proving effectiveness of the native vaccine construct for induction of T cell immune response. (Figure 6F  
482 and G). The results definitely showed that the T cell population was highly responsive as the memory  
483 response developed.

484

485 **Conclusion**

486 To our best knowledge, from the standpoint of immunoinformatics approaches, the concept discussed in  
487 this study is the first structural modeling to investigate both the TCR and pMHC interfaces for the SARS-  
488 CoV-2 proteins. Our results provide a blueprint for inferring the SARS-CoV-2-derived hit peptides with  
489 high accuracy towards vaccine development. Therefore, it is tempting to speculate that the aforementioned  
490 models will offer valuable framework for identifying specific peptides with a potential to activate T cell-  
491 mediated immune responses to target SARS-CoV-2. As a proof of concept, our study denotes a landmark  
492 in the advancement of immunoinformatics based method for designing a multi-hit peptides vaccine against  
493 the S and N protein of SARS-CoV-2. In addition, our innovative vaccine candidates can serve as promising  
494 tools towards fighting SARS-CoV-2 infections. Further *in vitro* and *in vivo* validation studies are necessary  
495 to confirm the safety and efficacy of T-cell-based immunotherapies using our vaccine proposed SARS-  
496 CoV-2 peptides.

497

498 **References**

- 499 1. Hui DS, Azhar EI, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, Mchugh TD, Memish ZA,  
500 Drosten C (2020) The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The  
501 latest 2019 novel coronavirus outbreak in Wuhan, China. *Int J Infect Dis* 91:264
- 502 2. Dong C, Ni L, Ye F, Chen M-L, Feng Y, Deng Y-Q, Zhao H, Wei P, Ge J, Li X, Sun L, Wang P, Liang  
503 P, Guo H, Wang X, Qin C-F, Chen F (2020) Characterization of anti-viral immunity in recovered  
504 individuals infected by SARS-CoV-2. medRxiv:2020.2003.2017.20036640.  
505 doi:10.1101/2020.03.17.20036640
- 506 3. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA, Sutherland A,  
507 Premkumar L, Jadi RS, Marrama D, de Silva AM, Frazier A, Carlin AF, Greenbaum JA, Peters B,  
508 Krammer F, Smith DM, Crotty S, Sette A (2020) Targets of T Cell Responses to SARS-CoV-2  
509 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* 181(7):1489-1501
- 510 4. Yang J, Wang W, Chen Z, Lu S, Yang F, Bi Z, Bao L, Mo F, Li X, Huang Y, Hong W, Yang Y, Zhao Y,  
511 Ye F, Lin S, Deng W, Chen H, Lei H, Zhang Z, Luo M, Gao H, Zheng Y, Gong Y, Jiang X, Xu Y, Lv Q, Li  
512 D, Wang M, Li F, Wang S, Wang G, Yu P, Qu Y, Yang L, Deng H, Tong A, Li J, Wang Z, Yang J, Shen G,  
513 Zhao Z, Li Y, Luo J, Liu H, Yu W, Yang M, Xu J, Wang J, Li H, Wang H, Kuang D, Lin P, Hu Z, Guo W,  
514 Cheng W, He Y, Song X, Chen C, Xue Z, Yao S, Chen L, Ma X, Chen S, Gou M, Huang W, Wang Y, Fan  
515 C, Tian Z, Shi M, Wang F-S, Dai L, Wu M, Li G, Wang G, Peng Y, Qian Z, Huang C, Lau JY-N, Yang Z,  
516 Wei Y, Cen X, Peng X, Qin C, Zhang K, Lu G, Wei X (2020) A vaccine targeting the RBD of the S protein  
517 of SARS-CoV-2 induces protective immunity. *Nature*. doi:10.1038/s41586-020-2599-8
- 518 5. Ahmed SF, Quadeer AA, McKay MR (2020) Preliminary identification of potential vaccine targets for  
519 the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. *Viruses*  
520 12(3):254
- 521 6. Banerjee A, Santra D, Maiti S (2020) Energetics based epitope screening in SARS CoV-2 (COVID 19)  
522 spike glycoprotein by Immuno-informatic analysis aiming to a suitable vaccine development. *BioRxiv*
- 523 7. Baruah V, Bose S (2020) Immunoinformatics-aided identification of T cell and B cell epitopes in the  
524 surface glycoprotein of 2019-nCoV. *J Med Virol*

- 525 8. Kumar S, Maurya VK, Prasad AK, Bhatt ML, Saxena SK (2020) Structural, glycosylation and antigenic  
526 variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV).  
527 *VirusDisease*:1-9
- 528 9. Fast E, Chen B (2020) Potential T-cell and B-cell Epitopes of 2019-nCoV. *BioRxiv*
- 529 10. Zheng M, Song L (2020) Novel antibody epitopes dominate the antigenicity of spike glycoprotein in  
530 SARS-CoV-2 compared to SARS-CoV. *Cell Mol Immunol*:1-3
- 531 11. Cao X (2020) COVID-19: immunopathology and its implications for therapy. *Nat Rev Immunol*:1-2
- 532 12. Kass I, Buckle AM, Borg NA (2014) Understanding the structural dynamics of TCR-pMHC  
533 interactions. *Trends Immunol* 35(12):604-612
- 534 13. Jensen KK, Rantos V, Jappe EC, Olsen TH, Jespersen MC, Jurtz V, Jessen LE, Lanzarotti E, Mahajan S,  
535 Peters B (2019) TCRpMHCmodels: Structural modelling of TCR-pMHC class I complexes. *Sci Rep*  
536 9(1):1-12
- 537 14. Michielin O, Luescher I, Karplus M (2000) Modeling of the TCR-MHC-peptide complex. *J Mol Biol*  
538 300(5):1205-1235
- 539 15. Liu I-H, Lo Y-S, Yang J-M (2013) Genome-wide structural modelling of TCR-pMHC interactions.  
540 *BMC Genom* 14(5):S5
- 541 16. Calis JJ, Maybeno M, Greenbaum JA, Weiskopf D, De Silva AD, Sette A, Keşmir C, Peters B (2013)  
542 Properties of MHC class I presented peptides that enhance immunogenicity. *PLoS Comput Biol* 9(10)
- 543 17. Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A (2020) A Sequence Homology and  
544 Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. *Cell host*  
545 *microbe* 27(4):671-680 e672. doi:10.1016/j.chom.2020.03.002
- 546 18. Yang J, Wang W, Chen Z, Lu S, Yang F, Bi Z, Bao L, Mo F, Li X, Huang Y, Hong W, Yang Y, Zhao  
547 Y, Ye F, Lin S, Deng W, Chen H, Lei H, Zhang Z, Luo M, Gao H, Zheng Y, Gong Y, Jiang X, Xu Y, Lv Q,  
548 Li D, Wang M, Li F, Wang S, Wang G, Yu P, Qu Y, Yang L, Deng H, Tong A, Li J, Wang Z, Shen G,  
549 Zhao Z, Li Y, Luo J, Liu H, Yu W, Yang M, Xu J, Wang J, Li H, Wang H, Kuang D, Lin P, Hu Z, Guo W,  
550 Cheng W, He Y, Song X, Chen C, Xue Z, Yao S, Chen L, Ma X, Chen S, Gou M, Huang W, Wang Y, Fan  
551 C, Tian Z, Shi M, Wang FS, Dai L, Wu M, Li G, Peng Y, Qian Z, Huang C, Lau JY, Yang Z, Wei Y, Cen

- 552 X, Peng X, Qin C, Zhang K, Lu G, Wei X (2020) A vaccine targeting the RBD of the S protein of SARS-  
553 CoV-2 induces protective immunity. *Nature* 29(10):020-2599
- 554 19. Anasir MI, Poh CL (2019) Structural Vaccinology for Viral Vaccine Design. *Front Microbiol* 10(738).  
555 doi:10.3389/fmicb.2019.00738
- 556 20. Adiyaman R, McGuffin LJ (2019) Methods for the Refinement of Protein Structure 3D Models. *Int J*  
557 *Mol Sci* 20(9)
- 558 21. Yadav BS, Tripathi V, Kumar A, Khan MF, Barate A, Sharma B (2012) Molecular modeling and  
559 docking characterization of Dectin-1 (PAMP) receptor of *Bubalus bubalis*. *Exp Mol Pathol* 92(1):7-12
- 560
- 561

562

563 **Figure Legends**

564 Figure 1. Overview of the amino acid profiles of the homologous peptide antigens related to the SARS-  
565 COV-2 N and S proteins associated with HLA-A0201 (A), HLA-E (B), HLA-B3501 (C), HLA-B3508 (D),  
566 HLA-B4405 (E), and HLA-B0801 (F) in TCR-pMHC complex template.

567

568 Figure 2. Comparison of the hydrophobicity of each hit peptide position related to SARS-CoV-2 by using  
569 the Wimley-White whole-residue hydrophobicity scales. Values less than zero represent greater  
570 hydrophobicity in each position of hit peptide. A: Comparison of the hydrophobicity of hit peptide derived  
571 from M protein Vs N protein in HLA-A0201; B: Hydrophobicity of hit peptide derived from N protein in  
572 HLA-B3501; C: Hydrophobicity of hit peptide derived from S protein in HLA-B0801; D: Comparison of  
573 the hydrophobicity of hit peptide derived from M protein Vs S protein in HLA-B4405; E: Comparison of  
574 the hydrophobicity of hit peptide derived from ORF10 protein Vs N protein in HLA-E; F: Hydrophobicity  
575 of hit peptide derived from S protein in HLA-B03508.

576

577 Figure 3. Amino acid sequence alignment of hit peptides derived from N and S proteins related to SARS-  
578 CoV-2, SARS-CoV, bat-CoV, and MERS-CoV by using the program CLC Sequence Viewer (Version  
579 6.7.1). Upper panel: Amino acid sequence alignment of hit peptides derived from N proteins in HLA-  
580 A0201 (A), HLA-E (C), and HLA-B3501 (E); Bottom panel: Amino acid sequence alignment of hit  
581 peptides derived from S proteins in HLA-B0801 (B), HLA-B4405 (D), and HLA-B3508 (F).

582

583 Figure 4. A: Successful peptide-protein docking between hit peptide derived from N protein  
584 (SPRWYFYLYL) and HLA-A0201 with cluster density scores of 219; B: Successful peptide-protein  
585 docking between hit peptide derived from S protein (FSTFKCYGV) and HLA-B0801 with cluster density  
586 scores of 272; C: Successful peptide-protein docking between hit peptide derived from N protein  
587 (NSSPDDQIGYY) and HLA-B3501 with cluster density scores of 270; D: Successful peptide-protein  
588 docking between hit peptide derived from S protein (NKKFLPFQQF) and HLA-B4405 with cluster density  
589 scores of 178; E: Successful peptide-protein docking between hit peptide derived from S protein



590 (LQDVVNQNAQALN) and HLA-B3508 with cluster density scores of 209; F: Successful peptide-protein  
591 docking between hit peptide derived from N protein (DLSPRWYFY) and HLA-E with cluster density  
592 scores of 215.

593

594 Figure 5: A and B: Schematic structure of the predicted model of the vaccine: The 3D structure of the  
595 designed vaccine was suggested through homology modeling by I-TASSER with C-score = -3.25,  
596 Estimated TM-score =  $0.35 \pm 0.12$ , and Estimated RMSD =  $11.7 \pm 4.5 \text{ \AA}$  (C-score shows the confidence of  
597 model, Estimated TM-score and RMSD are based on C-score and protein length following the correlation  
598 discovered between these qualities), then the best proposed model was refined by 3D<sup>refine</sup>. On the basis of  
599 the overall quality of the refined model, the model 5 exhibited the best results with RMSD 0.549 Å. Higher  
600 score indicates aggressive refinement. The figure 5A and B are in symmetry with the information provided  
601 in Table 3 and showing the interacting residues; C and D: ProSA-web Z-score plot. ProSA-web Z-score  
602 observed by NMR spectroscopy (dark blue) and X-ray crystallography (light blue) based on the length. The  
603 Z-score of the model before (C) and after (D) refinement were -3.45 and -3.81, respectively, which is in  
604 the range of native protein conformations; E and F: Ramachandran plot of the modeled vaccine construct  
605 before (E) and after (F) of refinement: Ramachandran plot of the model before refinement showed that  
606 54.2% and 78.3% of residues were located in the favored, allowed, respectively (E). While, Ramachandran  
607 plot of the model after refinement showed that 77.5% and 90% of residues were located in the favored,  
608 allowed, respectively (F).

609

610 Figure 6: In-silico T cell immune response simulation after administering native and mutant vaccine  
611 construct. A: Alignment between native and mutant vaccine construct (HP: hit peptide and L: linker). B-E:  
612 CD4 T-helper lymphocytes count after vaccination with native (B and D) and mutant construct (C and E):  
613 The plot displays total and memory counts. F-G: CD8 T-cytotoxic lymphocytes count after vaccination  
614 with native (F) and mutant construct (G). The plot shows total counts.

615

616 Figure S1. Overall structure of TCR-pMHC complex of SARS-CoV-2 proteins linked to HLA-A0201 (A),  
617 HLA-B3501 (B), HLA-B4405 (C), HLA-B0801 (D), HLA-B3508 (E), and HLA-E (F). Hit peptides (Chain





618 C), TCR (Chain E), TCR (Chain D), and MHC (Chain A) are colored purple, blue, red, and green,  
619 respectively.







620 Figure S2: Schematic representation of binding events of both p-MHC and p-TCR interfaces. Atomic  
621 binding models with H-bonds are represented by pink and blue lines, respectively. Also, VDW forces are  
622 presented. TCR chain D: yellow spiral lines, TCR chain E: pink spiral lines, MHC chain A: blue spiral lines.  
623







624 Figure S3. Graphic illustration of the interatomic contacts of SARS-CoV-2-derived hit peptide within TCR-  
625 pMHC complex for N and S proteins associated with various HLA by using PyMOL. MHC (chain A), hit  
626 peptide (chain C), and TCR (chain D and E) are represented by blue, red, yellow, and green color,  
627 respectively. Dashed bonds are used to visualize interatomic interactions of hit peptide within TCR-pMHC  
628 complex. VDW interactions and VDW clash interactions: gray, H-bonds: red, Weak H-bonds: orange,  
629 Aromatic contacts: blue, Hydrophobic contacts: green, Carbonyl interactions: light magenta. Distance of  
630 the interaction, overlapping the radii of VDW, and interactions associated with proximal is denoted by the  
631 thickness, thickest, and thinnest dashes, respectively.

632

633 Figure S4. WebGL-based visualization of interatomic interactions between chain C (hit peptide) and their  
634 TCR and MHC molecules belong to the SARS-CoV-2 compared to SARS-CoV, Bat-CoV, and MERS-CoV  
635 for HLA-A0201 (A), HLA-B0801 (B), HLA-B3501(C), HLA-B3508 (D), HLA-B4405 (E), and HLA-E (F).



















**A****Hit peptide: SPRWYFYLL**

bioRxiv preprint doi: <https://doi.org/10.1101/2020.09.12.294413>; this version posted September 12, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

**HLA-A0201****B****Hit peptide: FSTFKCYGV****HLA-B0801****C****Hit peptide: NSSPDDQIGYY****HLA-B3501****D****Hit peptide: NKKFLPFQQF****HLA-B4405****E****Hit peptide: LQDVVNQNAQALN****HLA-B3508****F****Hit peptide: DLSRWYFY****HLA-E**







**A****B****C****D****E****F**

**A**

HP L HP L HP L HP L HP

Native Vaccine DLSPRWYFYLAAYNSSPDDQIGYYGPGPGFSTFKCYGVGPGPLQDVVNQNAQALNGP GPGNKKFLPFQQF

Mutant Vaccine DDSPRWYFYEDAAYNSSPDDQDGDGPGPGFSTKKCYGVGPGPDQDVVNQNAQADNNGP GPGDKKFDPFQQF





**Table 1: Hit peptide derived from TCR-pMHC complex**

Virus	Protein	Peptide	Length (mer)	Position	Joint Z-value	Best Template (PDB)		
SARS-CoV-2	HLA-A0201	E	LFLAFVVFL	9	19 - 27	4.74	1qrn	
		M	SMWSFNPET	9	108 - 116	5.64	2jcc	
		N	SPRWYFYYL	9	105 - 113	4.37	2vlr	
		ORF3a	YFLCWHTNC	9	145 - 153	5.32	2p5e	
		ORF10	NVFAFPFTI	9	5.0 - 13	4.96	1oga	
		S	SIIAYTMSL	9	691 - 699	4.51	1oga	
	HLA-B0801	S	FSTFKCYGV	9	374 - 382	4.75	1mi5	
	HLA-B3501	N	NSSPDDQIGYY	11	77 - 87	4.26	2nx5	
	HLA-B3508	S	LQDVVNQNAQALN	13	948 - 960	4.12	2ak4	
	HLA-B4405	M	DSGFAAYSRY	10	190 - 199	4.09	3dxa	
		S	NKKFLPFQQF	10	556 - 565	4.2	3dxa	
	HLA-E	N	DLSRWYFY	9	103 - 111	4.25	2esv	
		ORF10	RMNSRNYIA	9	20 - 28	4.18	2esv	
		S	YLQPRTFLL	9	269 - 277	5.82	2esv	
	Bat-CoV	HLA-0201	E	LFLAFVVFL	9	19 - 27	4.74	1qrn
M			SMWSFNPET	9	108 - 116	5.64	2jcc	
N			SPRWYFYYL	9	105 - 113	4.37	2vlr	
Protein 3			YFLCWHTNC	9	145 - 153	5.32	2p5e	
S			AVYSFYANC	9	156 - 164	4.87	2jcc	
HLA-B0801			S	FSTFKCYGV	9	369 - 377	4.75	1mi5
HLA-B3501		N	QALPQRQKKQQ	11	380 - 390	4.25	2nx5	
HLA-B3508		S	LQDVVNQNAQALN	13	920 - 932	4.12	2ak4	
HLA-B4405		M	DSGFAAYSRY	10	190 - 199	4.09	3dxa	
		S	SKRFQSFQQF	10	532 - 541	4.09	3dxa	
HLA-E		N	ELSPRWYFY	9	103 - 111	4.04	2esv	
		S	YLPKRTFML	9	264 - 272	5.22	2esv	
MERS-CoV		HLA-A0201	E	CMTGFNTLL	9	43 - 51	4.12	2uwe
			M	SAMMWISYF	9	87 - 95	4.96	2f54

	N	PRWYFYTYG	9	96 - 104	4.07	1lp9
	ORF3	TAFSKPLYV	9	20 - 28	4.62	2gj6
	S	YYNKWPWYI	9	1291 - 1299	4.5	1ao7
HLA-B0801	S	YPQGRYTSN	9	58 - 66	4.44	1mi5
HLA-B3501	N	-	-	-	-	-
HLA-B3508	S	-	-	-	-	-
	M	-	-	-	-	-
HLA-B4405	S	EQLLREYGQF	10	818 - 827	4.32	3dxa
	N	QLAPRWYFY	9	93 - 101	4.91	2esv
HLA-E	S	-	-	-	-	-
	E	LFLAFVVFL	9	19 - 27	4.74	1qrm
	M	SMWSFNPET	9	107 - 115	5.64	2jcc
HLA-A0201	N	SPRWYFYLL	9	106 - 114	4.37	2vlr
	ORF3	AFLAVFQSA	9	51 - 59	4.52	2j8u
	S	PLNDYGFYT	9	477 - 485	4.99	1qrm
HLA-B0801	S	FSTFKCYGV	9	361 - 369	4.75	1mi5
HLA-B3501	N	QPLPQRQKKQP	11	381 - 391	4.48	2nx5
HLA-B3508	S	LQDVVNQNAQALN	13	930 - 942	4.12	2ak4
	M	DSGFAAYNRY	10	189 - 198	4.1	3dxa
HLA-B4405	S	SKRFQPFQQF	10	542 - 551	4.09	3dxa
	N	ELSPRWYFY	9	104 - 112	4.04	2esv
HLA-E	S	FITQRNFFS	9	1085 - 1093	4.31	2esv

E: Envelope protein; M: Membrane glycoprotein; N: Nucleocapsid phosphoprotein; ORF: Open reading frame; S: Surface glycoprotein; HLA: Human leukocyte antigen

**Table 2: Summary of the interatomic interactions within chain C and their binding site interactions in the TCR-pMHC complex of SARS-CoV-2 proteins**

Interatomic interactions		HLA-A0201					HLA-B0801	HLA-B3501	HLA-B3508	HLA-B4405		HLA-E			
		M	E	N	ORF3a	ORF10	S	S	N	S	M	S	N	ORF10	S
Mutually Exclusive Interactions	VDW interactions	7	12	17	13	12	5	9	12	16	8	16	32	27	32
	VDW clash interactions	27	46	100	60	36	36	64	39	56	29	49	130	58	92
	Covalent interactions	0	1	7	2	0	0	3	0	1	0	1	6	1	5
	Covalent clash interactions	0	0	1	0	0	0	1	0	0	0	0	2	0	0
	Proximal	675	738	878	777	708	646	640	669	926	667	791	883	748	816
	Total	709	797	1003	852	756	687	717	720	999	704	857	1053	834	945
Polar Contacts	Polar contacts	18	12	16	23	14	16	20	15	23	15	17	24	24	20
	Weak polar contacts	10	18	31	16	15	17	23	13	26	17	22	43	29	39
	Total	28	30	47	39	29	33	43	28	49	32	39	67	53	59
Feature Contacts	Hydrogen bonds	16	13	15	16	14	13	16	10	18	11	14	16	16	16
	Weak hydrogen bonds	11	12	13	11	15	13	9	11	10	8	6	14	13	13
	Ionic interactions	0	0	0	1	0	0	0	2	0	5	2	1	0	0
	Aromatic contacts	2	10	40	14	6	0	4	2	0	7	7	99	0	49
	Hydrophobic contacts	49	125	99	76	82	66	86	34	62	41	90	142	46	96
	Carbonyl interactions	1	1	1	1	1	1	0	1	2	0	0	0	0	0
	Total	79	161	168	119	118	93	115	60	92	72	119	272	75	203

Chain C: Hit peptide; VDW: van der Waals (VDW) forces; E: Envelope protein; M: Membrane glycoprotein; N: Nucleocapsid phosphoprotein; ORF: Open reading frame; S: Surface glycoprotein; HLA: Human leukocyte antigen

**Table 3: Summary of the interatomic interactions in the vaccine construct**

<b>Interatomic interactions</b>		<b>Vaccine (Before refinement)</b>	<b>Vaccine (After refinement)</b>
Mutually Exclusive Interactions	VDW interactions	166	150
	VDW clash interactions	419	326
	Covalent interactions	2	2
	Covalent clash interactions	0	0
	Proximal	5479	5086
	Total	6060	5564
Polar Contacts	Polar contacts	187	207
	Weak polar contacts	210	178
	Total	397	385
Feature Contacts	Hydrogen bonds	140	137
	Weak hydrogen bonds	77	76
	Ionic interactions	28	23
	Aromatic contacts	40	34
	Hydrophobic contacts	327	316
	Carbonyl interactions	41	35
	Total	653	621

VDW: van der Waals (VDW) forces